The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted worse outcomes than in those patients without ctDNA, even in patients with a pathologic complete response (pCR), according to a study published in Cancer Research Communications.